Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Alexipharmic Drug Market Outlook from 2024 to 2034

Opioid overdose has become a major problem for governments in developing and developed countries, especially in the United States and the United Kingdom. With the surging number of governments legalizing prescription opioids, the risk of opioid abuse too rises.

This has pushed the demand for alexipharmic drugs. The alexipharmic drug market valuation is estimated to be a staggering US$ 3.80 billion in 2024 and is slated to reach US$ 6.50 billion by the end of 2034, growing at a decent CAGR of 5.40%.

Attributes Details
Market Value for 2024 US$ 3.80 billion
Projected Market Value for 2034 US$ 6.50 billion
Value-based CAGR of the Market for 2024 to 2034 5.40%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Alexipharmic Drug Industry Restraints

  • Internationally, the market is filled with counterfeit drugs and medications. This has made the general populace reluctant to buy these drugs in some parts of the world.
  • Ever-evolving government policies have also become one of the major challenges in front of manufacturers.

Comparative View of Adjacent Markets

The rising disposable income among the younger generation and their desire to lead a Western lifestyle has naturally generated an excellent demand for medications and solutions that relieve people from alcohol or opioid overdose.

The growth rates of the alcohol use disorder treatment market and the alcoholic hepatitis treatment market, along with their challenges and ongoing trends, have been jotted down below.

Based on these analytics, it can be confidently projected that the alcoholic hepatitis treatment market is likely to have a more promising future in comparison to the other two.

Alexipharmic Drug Market:

Attributes Alexipharmic Drug Market
Value-based CAGR (2024 to 2034) 5.40%
Projected Market Value (2024) US$ 3.80 billion
Growth Factor Growing number of people, especially those living in urban and semi-urban parts of the world, are realizing the benefits of these counterpoisons primarily through social media and government campaigns
Restraint Lack of availability of these drugs in underdeveloped and developing areas due to low consumer demand and high price
Trend Companies collaborating with government bodies to effectively spread awareness about alexipharmic drugs

Alcohol Use Disorder Treatment Market:

Attributes Alcohol Use Disorder Treatment Market
Value-based CAGR (2024 to 2034) 6.4%
Growth Factor Increased government support, such as an increase in initiatives to improve consumer awareness about drug addiction, is likely to drive the market
Restraint Lack of knowledge of viable pharmacological therapy for AUD, particularly in emerging and underdeveloped nations
Trend Effective marketing strategies through social media campaigns and television ads increase the significance of these treatments

Alcoholic Hepatitis Treatment Market:

Attributes Alcoholic Hepatitis Treatment Market
Value-based CAGR (2024 to 2034) 6.5%
Growth Factor As more people consume alcohol, and in higher quantities, the incidence of liver diseases such as alcoholic hepatitis has been on rise
Restraints
  • Cost of treatment for alcoholic hepatitis can be high, particularly for advanced cases that require hospitalization or liver transplantation.
  • Limited access to treatment for some patients, particularly in developing and underdeveloped economies
Trends Advancements in technology in liver disease treatment are expected to provide new and improved treatment options for patients with alcoholic hepatitis
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Category-wise Insights

Consumers are Increasingly Preferring Alexipharmic Drugs for Opioid Overdose

Alexipharmic drugs are used for various purposes, such as opioid overdose, alcohol overdose, benzodiazepine overdose, etc. Among these, opioid overdose is in line to hold a majority market share of 39% in 2024.

Attributes Details
Application Opioid Overdose
Market Share (2024) 39%

Increased awareness among the general population about the opioid crisis and the importance of having access to naloxone and other counterpoisons have significantly impacted the market growth.

The effectiveness of counterpoisons like naloxone is also pushing consumers to prefer them for opioid overdose situations. With time and tide, the stigma around the use of counterpoisons has also made consumers more comfortable in using these drugs without being frowned upon.

Hospital Pharmacies are still the Number One Sales Channel for Alexipharmic Drugs

With the growing demand for counterpoisons in the general public, manufacturers are targeting various distribution channels for the sales of these drugs. Based on this, hospital pharmacies are poised to hold a majority share of 42% in this market in 2024.

Attributes Details
Distribution Channel Hospital Pharmacies
Market Share (2024) 42%

Hospital pharmacies are the number one destination for counterpoisons as they are often the first point of contact for individuals experiencing severe drug overdoses. Apart from this, medical professionals prescribe counterpoisons, which are seldom found outside of hospital pharmacies.

These hospital pharmacies are also generating huge demand for these drugs as they are closely integrated with other clinical services, including emergency departments and intensive care units.

Country-wise Insights

Countries CAGR (2024 to 2034)
South Korea 8.00%
Japan 7.10%
United Kingdom 6.70%
China 6.30%
United States 5.70%

South Korea’s Alexipharmic Drug Market to Benefit from Government’s Active Support

The market in South Korea is slated to grow at a CAGR of 8.00% through 2034. The government has been actively implementing various initiatives to mitigate the rising cases of alcohol and opioid overuse. For this, they have been promoting various counterpoisons such as naloxone.

The government’s support in the form of awareness campaigns, training, and accessibility, has created a conducive environment for the increasing adoption of counterpoisons in the country. The market is also growing in South Korea due to the increasing availability of these drugs across various distribution channels.

Rising Opioid Overdose to Profit Japan’s Alexipharmic Drug Market

The market in Japan is a promising one. It is anticipated to grow at a CAGR of 7.10% through 2034. Japan, in the last few years, has been reporting a substantial rise in opioid prescription rates, thanks to the influence of Western lifestyles on the younger generations in the country. This has created unprecedented demand for these drugs in the country.

The consumption of these drugs has also touched the skies as there has been a shift in public attitudes towards drug addiction. With increasing recognition of the need for harm reduction measures such as naloxone distribution programs, the market is set to benefit.

The United Kingdom to Exhibit Healthy Market Growth in the Near Future

The market in the United Kingdom is very likely to flourish in the coming years. The market is expected to grow at a CAGR of 6.70% through 2034. According to a survey, the opioid crisis in the United Kingdom has reached its all-time peak as opiate-related drug poisoning deaths have increased by 388% since 1993 in England and Wales.

This has significantly increased the prominence of these drugs in the United Kingdom as more people seek medications and prescriptions during emergencies associated with opioid abuse. Community distribution programs conducted by the public as well as private entities are also benefiting the consumption of these drugs in the country.

Government Regulations in China Paves the Way for Alexipharmic Drug Market

The market in China is also among the lucrative ones. It is expected to grow at a CAGR of 6.30% through 2034. The government has made strict rules and regulations regarding the manufacturing, possession, and distribution of counterpoisons in the country.

This has instilled a sense of trust in these medications among the general population in China, which is appreciably increasing the consumption of these drugs in the country. The consumption of these drugs in the Chinese marketplace is observed to be more in the urban and semi-urban settings, as compared to the rural ones.

Opioid Epidemic to Shape the Future of the United States Market

The United States alexipharmic drug market is a lucrative one. It is estimated to grow at a CAGR of 5.70% through 2034. The country is currently facing the problem of opioid addiction among the general populace.

Each year, more than 15 million people in the United States consume prescription opioids. This automatically generates huge demand for these drugs in the country as the chances of overdose are very high.

Increasing awareness among the people, coupled with rising disposable income, is a key reason for the market’s growth in the country. Modern and sophisticated infrastructure and reduced stigma regarding the use of counterpoisons among individuals are also responsible for the growth of this market in the country.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Competitive Landscape

The alexipharmic drug market is filled with a multitude of companies vying for international dominance in the marketplace. These companies, being in the pharma industry for a prolonged period of time, have extended their market reach beyond international borders.

The advent of online medicine platforms, telemedicine, and last-mile-delivery services in developed and developing countries has also helped the market to flourish in the past few years.

Recent Developments

  • On December 14, 2023, Novo Nordisk acquired Alkermes’s Irish plant in Athlone for US$ 92.5 million, enhancing its manufacturing capacity. Alkermes, a leading manufacturer of these drugs, aimed to meet rising demand. The deal was expected to close by mid-2024, maintaining Alkermes's royalty revenues from existing products.
  • On June 29, 2023, Rockwell Medical announced a 3-year co-promotional collaboration with B. Braun Medical. B. Braun's sales force promoted Rockwell's hemodialysis concentrates products on the United States West Coast. B. Braun Medical, a leading manufacturer of counterpoisons, hailed the partnership as a significant commercial opportunity.
  • On April 8, 2024, Bausch Health Companies Inc., a prominent manufacturer of counterpoisons, filed a patent lawsuit against Amneal Pharmaceuticals for its liver disease drug. The lawsuit ensued after Amneal sought FDA approval for a generic version of Xifaxan (rifaximin) 550 mg tablets.
  • On March 28, 2024, Emergent BioSolutions Inc. expanded access to OTC naloxone, addressing the opioid crisis. The leading manufacturer of counterpoisons extended NARCAN® Nasal Spray's shelf life to 48 months, distributed 22 million doses, and maintained affordability, aiding overdose prevention efforts.
  • Ethypharm acquired Altan Pharma on June 18, 2021, expanding into the Spanish market. Altan Pharma, a prominent manufacturer of these drugs, specializes in injectable medicines for hospitals. The acquisition bolstered Ethypharm's Critical Care portfolio and R&D pipeline.
  • On January 23, 2024, Emergent BioSolutions extended the shelf life of naloxone nasal spray, approved by the FDA for over-the-counter use in spring 2023, from 3 to 4 years. The extension followed the FDA's request to ensure the availability of opioid overdose reversal agents.
  • In December 2023, the United States government urged federal facilities nationwide to stock overdose reversal medications like naloxone, advancing efforts to combat the overdose epidemic and save lives.
  • In August 2016, Claris Lifesciences secured USFDA approval for its generic Flumazenil injection, used to reverse the sedative effects of benzodiazepines in the American market. The approval followed an inspection by the FDA at the same manufacturing plant.

Key Companies

  • Alkermes, Inc.
  • B. Braun Melsungen AG
  • Bausch Health Companies Inc.
  • Emergent BioSolutions
  • Ethypharm S.A.

Key Coverage in the Alexipharmic Drug Market

  • Industry trends in alexipharmic drugs
  • Emerging markets for alexipharmic drugs
  • Regulatory approvals and guidelines for alexipharmic drugs
  • Market penetration strategies for alexipharmic drug manufacturers
  • Impact of clinical trials and research studies on alexipharmic treatments’ demand

Key Segments of the Alexipharmic Drug Industry

By Application:

  • Alcoholic Overdose
  • Opioid Overdose
  • Benzodiazepine Overdose
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Frequently Asked Questions

How Much is the Alexipharmic Drug Market Currently Worth?

The market is expected to be worth US$ 3.80 billion in 2024.

What is the Sales Forecast for Alexipharmic Drugs through 2034?

The market is expected to reach US$ 6.50 billion by 2034.

At What Rate is the Alexipharmic Drug Market Growing?

The market is in line to grow at a CAGR of 5.40% from 2024 to 2034.

Which are the Key Companies in the Alexipharmic Drug Market?

Alkermes, Inc., B. Braun Melsungen AG, Bausch Health Companies Inc., Emergent BioSolutions, and Ethypharm S. A. are some of the major players in the market.

What was the Value of the Alexipharmic Drug Market in 2023?

The valuation for the alexipharmic drug market in 2023 was US$ 3.60 billion.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Product Life Cycle Analysis

    3.5. Supply Chain Analysis

        3.5.1. Supply Side Participants and their Roles

            3.5.1.1. Manufacturer

            3.5.1.2. Mid-Level Participants (Traders)

            3.5.1.3. Wholesalers and Distributors

        3.5.2. Value Added and Value Created at Node in the Supply Chain

        3.5.3. List of Raw Material Suppliers

        3.5.4. List of Existing and Potential Buyer’s

    3.6. Investment Feasibility Matrix

    3.7. Value Chain Analysis

        3.7.1. Profit Margin Analysis

        3.7.2. Wholesalers and Distributors

        3.7.3. Retailers

    3.8. PESTLE and Porter’s Analysis

    3.9. Regulatory Landscape

        3.9.1. By Key Regions

        3.9.2. By Key Countries

    3.10. Regional Parent Market Outlook

    3.11. Production and Consumption Statistics

    3.12. Import and Export Statistics

4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034

    4.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis, 2019 to 2023

    4.2. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Projections, 2024 to 2034

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Application, 2019 to 2023

    5.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Application, 2024 to 2034

        5.3.1. Alcoholic Overdose

        5.3.2. Opioid Overdose

        5.3.3. Benzodiazepine Overdose

        5.3.4. Others

    5.4. Y-o-Y Growth Trend Analysis By Application, 2019 to 2023

    5.5. Absolute $ Opportunity Analysis By Application, 2024 to 2034

6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Distribution Channel, 2019 to 2023

    6.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Distribution Channel, 2024 to 2034

        6.3.1. Hospital Pharmacies

        6.3.2. Retail Pharmacies

        6.3.3. Online Pharmacies

        6.3.4. Others

    6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023

    6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034

7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Region, 2019 to 2023

    7.3. Current Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Region, 2024 to 2034

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Western Europe

        7.3.4. Eastern Europe

        7.3.5. South Asia and Pacific

        7.3.6. East Asia

        7.3.7. Middle East and Africa

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    8.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023

    8.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034

        8.2.1. By Country

            8.2.1.1. USA

            8.2.1.2. Canada

        8.2.2. By Application

        8.2.3. By Distribution Channel

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Application

        8.3.3. By Distribution Channel

    8.4. Key Takeaways

9. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    9.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023

    9.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Application

        9.2.3. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Application

        9.3.3. By Distribution Channel

    9.4. Key Takeaways

10. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    10.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023

    10.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. UK

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Western Europe

        10.2.2. By Application

        10.2.3. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Application

        10.3.3. By Distribution Channel

    10.4. Key Takeaways

11. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    11.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023

    11.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034

        11.2.1. By Country

            11.2.1.1. Poland

            11.2.1.2. Russia

            11.2.1.3. Czech Republic

            11.2.1.4. Romania

            11.2.1.5. Rest of Eastern Europe

        11.2.2. By Application

        11.2.3. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Application

        11.3.3. By Distribution Channel

    11.4. Key Takeaways

12. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    12.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023

    12.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Bangladesh

            12.2.1.3. Australia

            12.2.1.4. New Zealand

            12.2.1.5. Rest of South Asia and Pacific

        12.2.2. By Application

        12.2.3. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Application

        12.3.3. By Distribution Channel

    12.4. Key Takeaways

13. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    13.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023

    13.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Application

        13.2.3. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Application

        13.3.3. By Distribution Channel

    13.4. Key Takeaways

14. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    14.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023

    14.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Application

        14.2.3. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Application

        14.3.3. By Distribution Channel

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. USA

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2023

            15.1.2.1. By Application

            15.1.2.2. By Distribution Channel

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2023

            15.2.2.1. By Application

            15.2.2.2. By Distribution Channel

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2023

            15.3.2.1. By Application

            15.3.2.2. By Distribution Channel

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2023

            15.4.2.1. By Application

            15.4.2.2. By Distribution Channel

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2023

            15.5.2.1. By Application

            15.5.2.2. By Distribution Channel

    15.6. UK

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2023

            15.6.2.1. By Application

            15.6.2.2. By Distribution Channel

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2023

            15.7.2.1. By Application

            15.7.2.2. By Distribution Channel

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2023

            15.8.2.1. By Application

            15.8.2.2. By Distribution Channel

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2023

            15.9.2.1. By Application

            15.9.2.2. By Distribution Channel

    15.10. Poland

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2023

            15.10.2.1. By Application

            15.10.2.2. By Distribution Channel

    15.11. Russia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2023

            15.11.2.1. By Application

            15.11.2.2. By Distribution Channel

    15.12. Czech Republic

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2023

            15.12.2.1. By Application

            15.12.2.2. By Distribution Channel

    15.13. Romania

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2023

            15.13.2.1. By Application

            15.13.2.2. By Distribution Channel

    15.14. India

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2023

            15.14.2.1. By Application

            15.14.2.2. By Distribution Channel

    15.15. Bangladesh

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2023

            15.15.2.1. By Application

            15.15.2.2. By Distribution Channel

    15.16. Australia

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2023

            15.16.2.1. By Application

            15.16.2.2. By Distribution Channel

    15.17. New Zealand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2023

            15.17.2.1. By Application

            15.17.2.2. By Distribution Channel

    15.18. China

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2023

            15.18.2.1. By Application

            15.18.2.2. By Distribution Channel

    15.19. Japan

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2023

            15.19.2.1. By Application

            15.19.2.2. By Distribution Channel

    15.20. South Korea

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2023

            15.20.2.1. By Application

            15.20.2.2. By Distribution Channel

    15.21. GCC Countries

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2023

            15.21.2.1. By Application

            15.21.2.2. By Distribution Channel

    15.22. South Africa

        15.22.1. Pricing Analysis

        15.22.2. Market Share Analysis, 2023

            15.22.2.1. By Application

            15.22.2.2. By Distribution Channel

    15.23. Israel

        15.23.1. Pricing Analysis

        15.23.2. Market Share Analysis, 2023

            15.23.2.1. By Application

            15.23.2.2. By Distribution Channel

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Application

        16.3.3. By Distribution Channel

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Alkermes, Inc.

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

                17.1.1.5.2. Product Strategy

                17.1.1.5.3. Channel Strategy

        17.1.2. B. Braun Melsungen AG

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

                17.1.2.5.2. Product Strategy

                17.1.2.5.3. Channel Strategy

        17.1.3. Bausch Health Companies Inc.

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

                17.1.3.5.2. Product Strategy

                17.1.3.5.3. Channel Strategy

        17.1.4. Emergent BioSolutions

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

                17.1.4.5.2. Product Strategy

                17.1.4.5.3. Channel Strategy

        17.1.5. Ethypharm S. A.

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

                17.1.5.5.2. Product Strategy

                17.1.5.5.3. Channel Strategy

        17.1.6. Fresenius SE & Co. KGaA

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

                17.1.6.5.2. Product Strategy

                17.1.6.5.3. Channel Strategy

        17.1.7. Hikma Pharmaceuticals

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

                17.1.7.5.2. Product Strategy

                17.1.7.5.3. Channel Strategy

        17.1.8. Merck & Co., Inc.

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

                17.1.8.5.2. Product Strategy

                17.1.8.5.3. Channel Strategy

        17.1.9. Mylan N.V.

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

                17.1.9.5.2. Product Strategy

                17.1.9.5.3. Channel Strategy

        17.1.10. SGPharma Pvt. Ltd.

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

                17.1.10.5.2. Product Strategy

                17.1.10.5.3. Channel Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Recommendations

Healthcare

General Anesthesia Drugs Market

Published : September 2023

Healthcare

Antimetabolite Drugs Market

Published : September 2022

Explore Healthcare Insights

View Reports